Aussies who are classified as 'moderate to high risk' and are aged between 18 and 64 now qualify for the immunisation.

About one in three people will develop shingles in their lifetime and nearly all adults aged 50 years and older carry the inactive virus that causes it. But the the risk of develo ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get ...

The robot has provided surgeons with instruments that offer a greater range of movement than in conventional keyhole surgery State-of-the-art robotic surgery has helped improve treatment for ...

Today, where wellness is no longer a luxury but a necessity, Santa Clarita residents are discovering the transformative ...

Your roof is a major investment, and like any investment, you want it to last as long as possible. While roofs are designed to withstand years of weather and wear, their longevity largely depends on ...